<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115578</url>
  </required_header>
  <id_info>
    <org_study_id>EPA (AG) 33/2017 (5097)</org_study_id>
    <nct_id>NCT05115578</nct_id>
  </id_info>
  <brief_title>Remifentanil Effect-site Prediction by Algometry</brief_title>
  <official_title>Remifentanil Pharmacodynamics During Conscious Sedation From the Algometry Perspective. An Essential Standpoint to be Considered in Opioids Time-course Modelling Validation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study validates the pharmacodynamic analgesic predictions (effect) given by Minto's&#xD;
      remifentanil pharmacokinetic and dynamic model in conscious sedation. This standard model is&#xD;
      based on the electroencephalogram (EEG) changes induced by this opioid as a proxy for&#xD;
      describing the remifentanil analgesic effect, which might be only valid for high&#xD;
      concentrations. Validation of the standard remifentanil model for low concentrations under&#xD;
      sedation is needed for safer remifentanil administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to pharmacokinetic and-dynamic (PK/PD) models, the proper use of anesthetics&#xD;
      depends on the effect-sites mechanisms and the time-courses of action. This aspect is crucial&#xD;
      for the practitioners to target the desired effect-site concentrations of the drugs (drug&#xD;
      concentration at brain) by optimizing the drug administration using target control infusion&#xD;
      (TCI) systems operating under these model predictions.&#xD;
&#xD;
      For more than two decades, the pharmacodynamic properties of remifentanil relied on Minto's&#xD;
      model, which is based on processed EEG as the reference to quantify the analgesic effect and&#xD;
      effect-site concentration estimate. This remifentanil pharmacodynamic was modeled under&#xD;
      conditions administered to volunteers rapidly and at very high doses to induce substantial&#xD;
      changes in the spontaneous processed EEG. The experimental concentrations and infusion rates&#xD;
      are far from sedative levels, where the EEG has shown a clear response to hypnosis but not to&#xD;
      analgesia or nociception.&#xD;
&#xD;
      Under the hypothesis that pharmacological models should predict equally well the effects&#xD;
      induced by drugs at different concentrations levels, the purpose of this study is to evaluate&#xD;
      and validate the pharmacodynamic predictions given by Minto's model in patients under&#xD;
      conscious sedation using the algometry as a reference of nociception.&#xD;
&#xD;
      The study recruits 100 female patients scheduled for benign gynecological surgery divided&#xD;
      into three groups. A group of 35 patients receives a constant TCI effect-site target infusion&#xD;
      of 1.5 ng/ml of remifentanil for 25 min. The second group of 35 follow the same protocol with&#xD;
      a bolus of 1 mg of midazolam before the remifentanil infusion. The rest configures the&#xD;
      control group under saline solution.&#xD;
&#xD;
      Experimental data consist of basal algometry (pressure pain threshold) aside from BIS index,&#xD;
      blood pressure, and heart rate values and at time-points of 1.5, 5, 10, 15, 18, 20, and 25&#xD;
      minutes after induction.&#xD;
&#xD;
      Minto's remifentanil pharmacodynamic model validation relies on comparing the levels and&#xD;
      temporal evolution of the algometry measurements during the whole experiment concerning the&#xD;
      effect-site estimations provided by the TCI-pump Minto's model.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pressure pain threshold (PPT) Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry before starting the administration of remifentanil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure pain threshold (PPT) 1.5 minutes</measure>
    <time_frame>1.5 minutes</time_frame>
    <description>Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 1.5 minutes after starting the administration of remifentanil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure pain threshold (PPT) 5 minutes</measure>
    <time_frame>5 minutes</time_frame>
    <description>Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 5 minutes after starting the administration of remifentanil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure pain threshold (PPT) 10 minutes</measure>
    <time_frame>10 minutes</time_frame>
    <description>Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 10 minutes after starting the administration of remifentanil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure pain threshold (PPT) 15 minutes</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measurement of pressure pain threshold(0 - 1.000 kPa) by algometry 15 minutes after starting the administration of remifentanil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure pain threshold (PPT) 18 minutes</measure>
    <time_frame>18 minutes</time_frame>
    <description>Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 18 minutes after starting the administration of remifentanil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure pain threshold (PPT) 20 minutes</measure>
    <time_frame>20 minutes</time_frame>
    <description>Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 20 minutes after starting the administration of remifentanil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure pain threshold (PPT) 25 minutes</measure>
    <time_frame>25 minutes</time_frame>
    <description>Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 25 minutes after starting the administration of remifentanil.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion rate</measure>
    <time_frame>Continous measurements every 1 second for the whole experiment of 25 minutes</time_frame>
    <description>Remifentanil infusion rate (ml/h) administered during the experiment to the patient provided by the TCI system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remifentanil Plasma Concentration (Cp)</measure>
    <time_frame>Continous measurements every 1 second for the whole experiment of 25 minutes</time_frame>
    <description>Patient's remifentanil plasma concentration (ng/ml) evolution during the experiment given by Minto's model implemented in the TCI system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remifentanil Effect Concentration (Ce)</measure>
    <time_frame>Continous measurements every 1 second for the whole experiment of 25 minutes</time_frame>
    <description>Patient's remifentanil effect concentration (ng/ml) evolution during the experiment given by Minto's model implemented in the TCI system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age</measure>
    <time_frame>Single annotation.</time_frame>
    <description>Apart from standard anthropometric data (Weight, Height, etc), age is of significant relevance for evaluating the possible effect of age on the pharmacodynamic properties of remifentanil and the algometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP) Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline mean arterial pressure (mmHg) from standard hemodynamic monitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP) 1.5 min</measure>
    <time_frame>1.5 minutes</time_frame>
    <description>Measurement of mean arterial pressure (mmHg) 1.5 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP) 5 min</measure>
    <time_frame>5 minutes</time_frame>
    <description>Measurement of mean arterial pressure (mmHg) 5 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP) 10 min</measure>
    <time_frame>10 minutes</time_frame>
    <description>Measurement of mean arterial pressure (mmHg) 10 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP) 15 min</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measurement of mean arterial pressure (mmHg) 15 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP) 18 min</measure>
    <time_frame>18 minutes</time_frame>
    <description>Measurement of mean arterial pressure (mmHg) 18 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP) 20 min</measure>
    <time_frame>20 minutes</time_frame>
    <description>Measurement of mean arterial pressure (mmHg) 20 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP) 25 min</measure>
    <time_frame>25 minutes</time_frame>
    <description>Measurement of mean arterial pressure (mmHg) 25 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR) Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline measurement of heart rate (beats/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR) 1.5 min</measure>
    <time_frame>1.5 minutes</time_frame>
    <description>Measurement of heart rate (beats/min) 1.5 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR) 5 min</measure>
    <time_frame>5 minutes</time_frame>
    <description>Measurement of heart rate (beats/min) 5 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR) 10 min</measure>
    <time_frame>10 minutes</time_frame>
    <description>Measurement of heart rate (beats/min) 10 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR) 15 min</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measurement of heart rate (beats/min) 15 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR) 18 min</measure>
    <time_frame>18 minutes</time_frame>
    <description>Measurement of heart rate (beats/min) 18 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate (HR) 20 min</measure>
    <time_frame>20 minutes</time_frame>
    <description>Measurement of heart rate (beats/min) 20 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectrum (BIS) Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Baseline measurement of EEG Bispectral index (adimensional index from 0- to 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectrum (BIS) 1.5 minutes</measure>
    <time_frame>1.5 minutes</time_frame>
    <description>EEG Bispectral index (adimensional index from 0- to 100) 1.5 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectrum (BIS) 5 minutes</measure>
    <time_frame>5 minutes</time_frame>
    <description>EEG Bispectral index (adimensional index from 0- to 100) 5 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectrum (BIS) 10 minutes</measure>
    <time_frame>10 minutes</time_frame>
    <description>EEG Bispectral index (adimensional index from 0- to 100) 10 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectrum (BIS) 15 minutes</measure>
    <time_frame>15 minutes</time_frame>
    <description>EEG Bispectral index (adimensional index from 0- to 100) 15 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectrum (BIS) 20 minutes</measure>
    <time_frame>20 minutes</time_frame>
    <description>EEG Bispectral index (adimensional index from 0- to 100) 20 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectrum (BIS) 25 minutes</measure>
    <time_frame>25 minutes</time_frame>
    <description>EEG Bispectral index (adimensional index from 0- to 100) 25 minutes after starting the administration of remifentanil.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Conscious Sedation Failure During Procedure</condition>
  <arm_group>
    <arm_group_label>Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil</arm_group_label>
    <description>Group I of 35 patients received a constant TCI effect-site target infusion of 1.5 ng/ml of remifentanil for 25 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv</arm_group_label>
    <description>Group II of 35 patients received a constant TCI effect-site target infusion of 1.5 ng/ml of remifentanil for 25 min with a bolus of 1 mg of midazolam previous to the remifentanil infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III Control</arm_group_label>
    <description>Group III of 30 patients. The same TCI system provided the saline solution in the control group under an equivalent simulation profile to the remifentanil administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil 1 MG Injection [Ultiva]</intervention_name>
    <description>Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil.</description>
    <arm_group_label>Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil</arm_group_label>
    <arm_group_label>Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv</arm_group_label>
    <other_name>Opioid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam 1 MG/ML Prefilled Syringe</intervention_name>
    <description>Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv</description>
    <arm_group_label>Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv</arm_group_label>
    <other_name>Benzodiazepine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>Group III Control</description>
    <arm_group_label>Group III Control</arm_group_label>
    <other_name>0.9% Sodium Chloride Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Algometry</intervention_name>
    <description>The algometry technique is used to assess the pain pressure threshold as an analgesic effect of remifentanil concerning Minto's model prediction.</description>
    <arm_group_label>Group I TCI effect-site target infusion of 1.5 ng/ml of remifentanil</arm_group_label>
    <arm_group_label>Group II TCI effect-site target infusion of 1.5 ng/ml of remifentanil + 1 mg Midazolam iv</arm_group_label>
    <arm_group_label>Group III Control</arm_group_label>
    <other_name>Somedic Type II®, Sweden</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We enrolled 100 female patients scheduled for benign gynaecological surgery. A group of 35&#xD;
        patients received a constant TCI effect-site target infusion of 1.5 ng/ml of remifentanil&#xD;
        for 25 min. The second group of 35 followed the same protocol with a bolus of 1 mg of&#xD;
        midazolam previous to the remifentanil infusion to evaluate potential anxiolysis effects.&#xD;
        The rest configured to the control group.&#xD;
&#xD;
        Algometry was used to quantify pressure pain thresholds regarding basal measurements at&#xD;
        time-points of 1.5, 5, 10, 15, 18, 20, and 25 min after induction began beside the blood&#xD;
        pressure and heart rate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients scheduled for benign gynaecological surgery&#xD;
&#xD;
          -  18-80 years old&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  Conduct disorder or anxiety-depressive syndrome&#xD;
&#xD;
          -  Chronic treatment with psychotropic drugs or opiates&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Documented allergy to remifentanil or midazolam&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Abad-Torrent, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Vall d'Hebron Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ana Abad-Torrent</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Remifentanil</keyword>
  <keyword>Algometry</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>TCI Infusion system</keyword>
  <keyword>Conscious Sedation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

